Paolo Tarantino, 2025 Yvonne’s “Top Voice” Award Winner, Research Fellow at Dana-Farber Cancer Institute, Visiting Professor presso McGill University, shared a post on X:
“Negative press release from ASCENT-07: in patients with ER+ MBC refractory to endocrine treatment, first-line SG did not improve PFS compared with chemotherapy.
In this setting, T-DXd outperformed chemotherapy (DB-06) and a phase 3 is ongoing with Sac-TMT +/- pembro (TF-10).
The single most notable difference between DB06 vs ASCENT-7: DB06 had some form of biomarker selection (HER2-low and ultralow, 90% of pts with HR+/HER2- MBC), the latter had no selection. Biomarkers become more and more important as ADCs are tested in earlier line, where SoC works well.”
More posts featuring Paolo Tarantino.